Use of big data in drug development for precision medicine
暂无分享,去创建一个
[1] Todd R. Golub,et al. An ecosystem of cancer cell line factories to support a cancer dependency map , 2015, Nature Reviews Genetics.
[2] R. Jirtle,et al. Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers. , 1999, Cancer research.
[3] G. Getz,et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. , 2016, The New England journal of medicine.
[4] F. Pammolli,et al. The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.
[5] Y. Hoshida,et al. Cancer biomarker discovery and validation. , 2015, Translational cancer research.
[6] Natalie de Souza. Genomics: The ENCODE project , 2012, Nature Methods.
[7] Emilio Benfenati,et al. In silico methods to predict drug toxicity. , 2013, Current opinion in pharmacology.
[8] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[9] Michael Mitzenmacher,et al. Detecting Novel Associations in Large Data Sets , 2011, Science.
[10] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[11] Andrew L. Kung,et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.
[12] Gabor T. Marth,et al. An integrated map of structural variation in 2,504 human genomes , 2015, Nature.
[13] T. Golub. Counterpoint: Data first , 2010, Nature.
[14] G. Patlewicz,et al. An evaluation of the implementation of the Cramer classification scheme in the Toxtree software , 2008, SAR and QSAR in environmental research.
[15] N. Schork. Personalized medicine: Time for one-person trials , 2015, Nature.
[16] Takashi Gojobori,et al. TP Atlas: integration and dissemination of advances in Targeted Proteins Research Program (TPRP)—structural biology project phase II in Japan , 2012, Journal of Structural and Functional Genomics.
[17] Martin Caffrey,et al. A comprehensive review of the lipid cubic phase or in meso method for crystallizing membrane and soluble proteins and complexes , 2015, Acta crystallographica. Section F, Structural biology communications.
[18] Michael Eisenstein. GSK collaborates with Apple on ResearchKit , 2015, Nature Biotechnology.
[19] Andrew M Watkins,et al. Structure-based inhibition of protein-protein interactions. , 2015, European journal of medicinal chemistry.
[20] James Devillers,et al. Methods for building QSARs. , 2013, Methods in molecular biology.
[21] J. Falls,et al. Imprinted M6p/Igf2 receptor is mutated in rat liver tumors , 1998, Oncogene.
[22] ENCODEConsortium,et al. An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.
[23] Alessio Farcomeni,et al. A review of modern multiple hypothesis testing, with particular attention to the false discovery proportion , 2008, Statistical methods in medical research.
[24] Feng Luan,et al. Predicting multiple ecotoxicological profiles in agrochemical fungicides: a multi-species chemoinformatic approach. , 2012, Ecotoxicology and environmental safety.
[25] Benjamin M. Good,et al. Crowdsourcing for bioinformatics , 2013, Bioinform..
[26] D. Sargent,et al. Clinical trial designs incorporating predictive biomarkers. , 2016, Cancer treatment reviews.
[27] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[28] Geoffrey S Ginsburg,et al. Genomics-enabled drug repositioning and repurposing: insights from an IOM Roundtable activity. , 2014, JAMA.
[29] Carol A Marchant,et al. In Silico Tools for Sharing Data and Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic , 2008, Toxicology mechanisms and methods.
[30] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[31] Zhiyong Lu,et al. A survey of current trends in computational drug repositioning , 2016, Briefings Bioinform..
[32] H. Skirton,et al. Direct to consumer genetic testing: a systematic review of position statements, policies and recommendations , 2012, Clinical genetics.
[33] J. Dekker,et al. The long-range interaction landscape of gene promoters , 2012, Nature.
[34] Dieter Lang,et al. Predicting drug metabolism: experiment and/or computation? , 2015, Nature Reviews Drug Discovery.
[35] Adam A. Margolin,et al. Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas , 2013, Nature Genetics.
[36] D. Dix,et al. The ToxCast program for prioritizing toxicity testing of environmental chemicals. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[37] Kunal Roy,et al. QSAR modeling of toxicity of diverse organic chemicals to Daphnia magna using 2D and 3D descriptors. , 2010, Journal of hazardous materials.
[38] Todd R Golub,et al. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation , 2008, Proceedings of the National Academy of Sciences.
[39] Anette Küster,et al. Pharmaceuticals in the environment: scientific evidence of risks and its regulation , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.
[40] F. Collins,et al. A new initiative on precision medicine. , 2015, The New England journal of medicine.
[41] K. Stegmaier,et al. Genetic and proteomic approaches to identify cancer drug targets , 2011, British Journal of Cancer.
[42] L. Law. Origin of the Resistance of Leukæmic Cells to Folic Acid Antagonists , 1952, Nature.
[43] H. Sebastian Seung,et al. Learning the parts of objects by non-negative matrix factorization , 1999, Nature.
[44] Ferenc Darvas,et al. HazardExpert: An Expert System for Predicting Chemical Toxicity , 1992 .
[45] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[46] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[47] Richard J. Williams,et al. Predicted Exposures to Steroid Estrogens in U.K. Rivers Correlate with Widespread Sexual Disruption in Wild Fish Populations , 2005, Environmental health perspectives.
[48] Luke W. Koblan,et al. A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity , 2014, Nature chemical biology.
[49] Nadav S. Bar,et al. Landscape of transcription in human cells , 2012, Nature.
[50] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[51] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[52] J. DiMasi,et al. Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.
[53] Hugo Y. K. Lam,et al. Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.
[54] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[55] Jong Hwan Sung,et al. Using physiologically-based pharmacokinetic-guided “body-on-a-chip” systems to predict mammalian response to drug and chemical exposure , 2014, Experimental biology and medicine.
[56] M. Dickson,et al. Key factors in the rising cost of new drug discovery and development , 2004, Nature Reviews Drug Discovery.
[57] W. Hahn,et al. Identification of an “Exceptional Responder” Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy , 2015, Molecular Cancer Research.
[58] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[59] Fabrício F. Costa. Big data in biomedicine. , 2014, Drug discovery today.
[60] Marco Egbring,et al. Phynx: an open source software solution supporting data management and web‐based patient‐level data review for drug safety studies in the general practice research database and other health care databases , 2010, Pharmacoepidemiology and drug safety.
[61] Alexander A. Morgan,et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.
[62] Luke A. Gilbert,et al. Defining principles of combination drug mechanisms of action , 2012, Proceedings of the National Academy of Sciences.
[63] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[64] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[65] S. Ekins,et al. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.
[66] Todd R Golub,et al. Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation , 2004, Nature Genetics.
[67] Justin Lamb,et al. The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.
[68] David Killock. Lung cancer: A new generation of EGFR inhibition , 2015, Nature Reviews Clinical Oncology.
[69] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[70] Ruili Huang,et al. Integrated Model of Chemical Perturbations of a Biological Pathway Using 18 In Vitro High-Throughput Screening Assays for the Estrogen Receptor. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.
[71] L. Law. Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice. , 1952, Cancer research.
[72] Caroline McNeil,et al. NCI-MATCH launch highlights new trial design in precision-medicine era. , 2015, Journal of the National Cancer Institute.
[73] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[74] Beibei Guo,et al. Optimal two-stage enrichment design correcting for biomarker misclassification , 2018, Statistical methods in medical research.
[75] Benjamin S. Glicksberg,et al. Identification of type 2 diabetes subgroups through topological analysis of patient similarity , 2015, Science Translational Medicine.
[76] J. Fick,et al. Dilute Concentrations of a Psychiatric Drug Alter Behavior of Fish from Natural Populations , 2013, Science.
[77] William Stafford Noble,et al. Machine learning applications in genetics and genomics , 2015, Nature Reviews Genetics.
[78] J. Mesirov,et al. Metagene projection for cross-platform, cross-species characterization of global transcriptional states , 2007, Proceedings of the National Academy of Sciences.
[79] Helen R. Saibil,et al. Cryo electron microscopy to determine the structure of macromolecular complexes , 2016, Methods.
[80] Carol A. Mulrooney,et al. Diversity-Oriented Synthesis-Facilitated Medicinal Chemistry: Toward the Development of Novel Antimalarial Agents , 2014, Journal of medicinal chemistry.
[81] J. Minna,et al. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. , 2010, Cancer cell.
[82] R. Jirtle,et al. Disruption of Ligand Binding to the Insulin-like Growth Factor II/Mannose 6-Phosphate Receptor by Cancer-associated Missense Mutations* , 1999, The Journal of Biological Chemistry.
[83] A. Redig,et al. Basket trials and the evolution of clinical trial design in an era of genomic medicine. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] T. Golub,et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.
[85] Nathan C. Sheffield,et al. The accessible chromatin landscape of the human genome , 2012, Nature.
[86] Cyrus Mehta,et al. Biomarker-driven population enrichment for adaptive oncology trials with time to event endpoints. , 2016, Statistics in medicine.
[87] S. Vilar,et al. High-Throughput Methods for Combinatorial Drug Discovery , 2013, Science Translational Medicine.
[88] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[89] Yin-tak Woo,et al. OncoLogic: A Mechanism-Based Expert System for Predicting the Carcinogenic Potential of Chemicals , 2005 .
[90] Data production leads,et al. An integrated encyclopedia of DNA elements in the human genome , 2012 .